# A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

> **NCT04225156** · PHASE3 · COMPLETED · sponsor: **argenx** · enrollment: 101 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** efgartigimod

## Key facts

- **NCT ID:** NCT04225156
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-02
- **Primary completion:** 2026-03-11
- **Final completion:** 2026-03-11
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225156, "A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT04225156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*